Literature DB >> 20218735

Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling.

Jana Ferdin1, Tanja Kunej, George A Calin.   

Abstract

MicroRNAs (miRNAs) belong to the heterogeneous class of non-coding RNAs (ncRNAs), which are by definition RNA molecules that do not encode for proteins, but have instead important structural, catalytic or regulatory functions. In this review we first provide an overview of the different ncRNA families, focusing in particular on miRNAs and their relevance in tumour development and progression. Second we shortly describe the available ncRNA expression profiling methods, which comprise microarray, bead-based hybridization methods, in situ hybridization, quantitative real-time polymerase chain reaction, cloning and deep sequencing methods. Finally, we used the PubMed database to perform an extensive literature search for miRNA expression profiling research articles in cancer and identified 58 studies that were published between 2004 and 2009; we identified 70 miRNAs that were reported in at least five studies as being either up- or downregulated, depending on the type of cancer, and 192 miRNAs that were reported to be up- or downregulated in at least two reports. MiRNA expression profiling of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis, and response to treatment. Based on the most important findings we discuss the possible use of miRNAs as clinical biomarkers in the management of cancer patients for diagnosis, prognosis, and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218735     DOI: 10.1177/153303461000900202

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  31 in total

Review 1.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

2.  Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.

Authors:  Berrin Tunca; Gulcin Tezcan; Gulsah Cecener; Unal Egeli; Secil Ak; Hulusi Malyer; Gulendam Tumen; Ayhan Bilir
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

Review 3.  Cross talk between microRNA and coding cancer genes.

Authors:  Tanja Kunej; Irena Godnic; Simon Horvat; Minja Zorc; George A Calin
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 4.  Epigenetic linkage of aging, cancer and nutrition.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

5.  Dynamic evolution of mir-17-92 gene cluster and related miRNA gene families in vertebrates.

Authors:  Li Guo; Sheng Yang; Yang Zhao; Qian Wu; Feng Chen
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

Review 6.  Role of 3'-untranslated region translational control in cancer development, diagnostics and treatment.

Authors:  Andrii Vislovukh; Thaiz Rivera Vargas; Anna Polesskaya; Irina Groisman
Journal:  World J Biol Chem       Date:  2014-02-26

Review 7.  Small molecule compounds targeting miRNAs for cancer therapy.

Authors:  Paloma Del C Monroig; Lu Chen; Shuxing Zhang; George A Calin
Journal:  Adv Drug Deliv Rev       Date:  2014-09-17       Impact factor: 15.470

Review 8.  MicroRNAs in body fluids--the mix of hormones and biomarkers.

Authors:  Maria Angelica Cortez; Carlos Bueso-Ramos; Jana Ferdin; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Nat Rev Clin Oncol       Date:  2011-06-07       Impact factor: 66.675

Review 9.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

10.  miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

Authors:  Shujing Liu; Michael T Tetzlaff; Rutao Cui; Xiaowei Xu
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.